Madrigal Rezdiffra Sales Surge to $213 Million, Patent Extended to 2045

Madrigal Pharmaceuticals reported second-quarter revenue of $212.8 million, driven entirely by its liver-disease drug Rezdiffra. The once-daily treatment for metabolic dysfunction-associated steatohepatitis (MASH) has now been prescribed to more than 23,000 U.S. patients, the company said on Tuesday. The Pennsylvania-based biotech ended June with $802 million in cash and marketable securities. In July it bolstered liquidity through a senior secured credit agreement with funds managed by Blue Owl Capital, giving the company access to as much as $500 million, including an initial $350 million draw used in part to refinance existing debt. Madrigal also disclosed that the U.S. Patent and Trademark Office is issuing a new patent that secures Rezdiffra exclusivity until 4 February 2045. Regulatory momentum continued overseas, where the European Medicines Agency’s CHMP issued a positive opinion recommending approval of Rezdiffra for MASH, with a final European Commission decision expected in August.